Best selling report

Personalized Medicine Partnering Terms and Agreements

The Personalized Medicine Partnering Terms & Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies..... More

Featured partnering deals

Probi signs a pharma deal with big pharma Sanofi

April 16, 2014 : big pharma, partnering, pharma deals, Sanofi

Probi has signed a pharma deal for distribution and supply with Sanofi for Digestis. more »

Aveo and Biodesix sign a pharma alliance for companion diagnostic test

April 15, 2014 : biotech, companion diagnostic, diagnostic, pharma deals

AVEO Oncology and Biodesix entered into a worldwide pharma alliance to develop and commercialize AVEO’s hepatocyte growth factor inhibitory antibody ficlatuzumab, with a Biodesix companion diagnostic test. more »

 More partnering deals


Featured M&A deals

Mallinckrodt scoops up Questcor in a m&a deal

April 8, 2014 : acquisition, big biotech, big pharma, biotech, M&A

Mallinckrodt and Questcor Pharmaceuticals have entered into a definitive m&a agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. more »

Sun Pharma and Ranbaxy engage in M&A transaction

April 7, 2014 : acquisition, Daiichi Sankyo, M&A, Ranbaxy

Sun Pharmaceutical agreed to m&a transaction to buy competitor Ranbaxy Laboratories for $3.2 billion from Japan’s Daiichi Sankyo, which paid 61 percent more for the company five years ago. more »

 More M&A deals

Featured financing deals

Nexvet closes $31.5 million in financing

April 17, 2014 : financing, financings

Nexvet Biopharma announced the closing of its US$31.5 million Series B round of financing. more »

Epirus gets $36 million in Series B financing

April 17, 2014 : financing, financings

Epirus also announced today that it has closed a $36 million Series B financing round led by Livzon Mabpharm, Inc. more »

 More financing deals

Latest Dealtalk

Meda rejects Mylan M&A approach

April 7, 2014 : dealtalk, M&A

Swedish generic drugmaker Meda AB rejected a M&A approach by U.S. rival Mylan Inc to create a combined company worth around $24 billion. more »

Smith & Nephew recommended for 3-way split

March 31, 2014 : dealtalk

Smith & Nephew  is suggested to split itself in 3-way by  Investec. more »

 More dealtalk

Featured reports

Companion Diagnostics Partnering Terms and Agreements

Publication date: April 2014

Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Biomarker Partnering Terms and Agreements

Publication date: April 2014

Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Orphan Diseases Partnering Terms and Agreements

Publication date: April 2014

Partnering Deals and Alliances with Big Pharma

Publication date: March 2014

Regenerative Medicine and Stem Cells Partnering Terms and Agreements

Publication date: March 2014

 

NEW: Therapy deal reports covering all major indications

Including partnering in oncology, cardiovascular, CNS, metabolic, dermatology, dental, infectives, immunologypsychiatry, genitourinary.....plus many others

View all reports

Recent therapy insights

Blog in Blog: There are no posts that match the selection criteria. View all points of view articles

Scorecard

Current Partnering provides access to key deal metrics for all leading partnering, M&A and financings - plus big pharma partnering activity and R&D spend metrics.

Available scorecards:

Partnering

M&A

Financing

Top 50 pharma partnering

Top 50 biotech partnering

Top pharma R&D spend

Deal metrics - by stage of development, therapy area, industry sector

Print Friendly
bannerpng
RSS Feed Linked In Twitter

Latest Tweets

cp300x1502gif
biovariabanner300x150gif
current-partnering-300x150-orphanjpg